Diarrhea News and Research

Latest Diarrhea News and Research

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Patients with chronic constipation prefer Kristalose oral solution

Cumberland Pharmaceuticals Inc. today announced the publication of a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to liquid lactulose products.

2 Dec 2010

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.

2 Dec 2010

Worm eggs may heal ulcerative colitis: Research

A new study involving a man who swallowed worm eggs to relieve symptoms of ulcerative colitis sheds light on how worms promote healing in the intestine. The study, published today in Science Translational Medicine, also identifies potential targets for more conventional ways of treating colitis, an inflammatory bowel disease.

2 Dec 2010

Arsenic contamination of drinking water in Bangladesh leads to slow-developing diseases

The well-reported arsenic contamination of drinking water in Bangladesh called the "largest mass poisoning of a population in history" by the World Health Organization and known to be responsible for a host of slow-developing diseases has now been shown to have an immediate and toxic effect on the struggling nation's economy.

1 Dec 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Sucampo Pharmaceuticals, Inc. and Abbott today announced positive top-line data from a 48-week phase 3 long-term safety and efficacy clinical trial of lubiprostone in Japanese patients with chronic idiopathic constipation (CIC). The trial demonstrated that lubiprostone was safe and well-tolerated.

30 Nov 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

AMAG updates product label of Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme (ferumoxytol) Injection for intravenous (IV) use.

29 Nov 2010

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

Specialists suggest U.S. should stockpile cholera vaccines for rapid deployment at disease outbreak

As the cholera epidemic in Haiti continues to rage, public health workers are focusing their efforts on treating the tens of thousands who have already been hospitalized with cholera-like symptoms and providing clean water and adequate sanitation to control the disease's spread.

25 Nov 2010

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

23 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Amgen announces final study results of Nplate in adults with chronic ITP

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Patients with chronic constipation prefer Kristalose oral solution

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

Worm eggs may heal ulcerative colitis: Research

Arsenic contamination of drinking water in Bangladesh leads to slow-developing diseases

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Merck announces initial results from ISENTRESS Phase III study in HIV-1

AMAG updates product label of Feraheme Injection

Immunity-enhancing probiotics may be the best line of defense for good health

Specialists suggest U.S. should stockpile cholera vaccines for rapid deployment at disease outbreak

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Vertex submits NDA for telaprevir for treating hepatitis C

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in